title: Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
abstract: Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases worldwide. Despite all the efforts made by the scientific community, current available treatments have limited effectiveness, without halting the progression of the disease. That is why, new molecules such as growth factors, antioxidants and metal chelators have been raised as new therapeutical approaches. However, these molecules have difficulties to cross the blood-brain barrier limiting its therapeutic effect. The development of nanometric drug delivery systems may permit a targeted and sustained release of old and new treatments offering a novel strategy to treat these neurodegenerative disorders. This review summarized the main investigated drug delivery systems as promising approaches to treat Alzheimer's disease and Parkinson's disease.
authors.affiliation: NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain.|Biomedical Research Networking Centre in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain.
authors.forename: Sara
authors.initials: S
authors.lastname: Hernando
authors.affiliation: NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain.|Biomedical Research Networking Centre in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain.
authors.forename: Oihane
authors.initials: O
authors.lastname: Gartziandia
authors.affiliation: NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain.|Biomedical Research Networking Centre in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain.
authors.forename: Enara
authors.initials: E
authors.lastname: Herran
authors.affiliation: NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain.|Biomedical Research Networking Centre in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain.
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Pedraz
authors.affiliation: NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain.|Biomedical Research Networking Centre in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain.
authors.forename: Manoli
authors.initials: M
authors.lastname: Igartua
authors.affiliation: NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain.|Biomedical Research Networking Centre in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain.
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Hernandez
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D055808:Drug Discovery; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D004337:Drug Carriers; D018696:Neuroprotective Agents
keywords: Alzheimer’s disease; Parkinson’s disease; drug delivery systems; nanomedicine; nanotechnology